In Brief: FDA Oversight hearing
Executive Summary
FDA Oversight hearing: Witnesses scheduled to testify June 19 before the House Commerce/Oversight Subcommittee include Tufts' Louis Lasagna, MD, Wilkes University's Arthur Kibbe, PhD, National Coalition for Cancer Survivorship Executive Director Ellen Stovall and Genzyme VP-Clinical, Medical & Regulatory Affairs Richard Moscicki, MD. Lasagna was previously scheduled to testify before the subcommittee May 25 but could not appear due to travel difficulties. Kibbe, while an official with the American Pharmaceutical Association, was one of three consultants who authored a report on the generic drug review process in 1991...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth